BeiGene, Ltd. (NASDAQ:BGNE) Shares Purchased by Handelsbanken Fonder AB

Handelsbanken Fonder AB increased its position in BeiGene, Ltd. (NASDAQ:BGNEGet Rating) by 10.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,853 shares of the company’s stock after acquiring an additional 2,053 shares during the period. Handelsbanken Fonder AB’s holdings in BeiGene were worth $2,946,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC raised its stake in BeiGene by 8.5% in the 3rd quarter. Janney Montgomery Scott LLC now owns 1,895 shares of the company’s stock worth $255,000 after acquiring an additional 149 shares during the last quarter. Whittier Trust Co. of Nevada Inc. purchased a new position in BeiGene in the 3rd quarter worth $165,000. Sumitomo Mitsui Trust Holdings Inc. raised its stake in BeiGene by 1.6% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 119,380 shares of the company’s stock worth $16,095,000 after acquiring an additional 1,853 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in BeiGene in the 3rd quarter worth $61,000. Finally, Harbour Capital Advisors LLC purchased a new position in BeiGene in the 3rd quarter worth $379,000. Hedge funds and other institutional investors own 51.43% of the company’s stock.

BeiGene Price Performance

NASDAQ:BGNE opened at $245.95 on Tuesday. BeiGene, Ltd. has a 52 week low of $118.18 and a 52 week high of $257.31. The company has a quick ratio of 3.87, a current ratio of 4.07 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $25.54 billion, a PE ratio of -11.52 and a beta of 0.78. The stock’s 50-day moving average price is $203.21 and its 200-day moving average price is $179.92.

Insider Activity

In other news, CEO John Oyler sold 1,716 shares of the firm’s stock in a transaction dated Thursday, December 29th. The stock was sold at an average price of $224.46, for a total transaction of $385,173.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, insider Xiaodong Wang sold 3,013 shares of BeiGene stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $211.33, for a total value of $636,737.29. Following the sale, the insider now directly owns 5,577,556 shares in the company, valued at approximately $1,178,704,909.48. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO John Oyler sold 1,716 shares of BeiGene stock in a transaction dated Thursday, December 29th. The stock was sold at an average price of $224.46, for a total value of $385,173.36. The disclosure for this sale can be found here. Insiders have sold 32,836 shares of company stock worth $6,861,664 in the last ninety days. Company insiders own 7.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. SVB Leerink raised their target price on BeiGene from $210.00 to $236.00 and gave the stock an “outperform” rating in a research note on Monday, December 12th. Guggenheim lifted their price objective on BeiGene to $210.00 in a research note on Tuesday, November 15th. Morgan Stanley lifted their price objective on BeiGene from $290.00 to $295.00 and gave the company an “overweight” rating in a research note on Thursday, October 13th. StockNews.com upgraded BeiGene from a “sell” rating to a “hold” rating in a research note on Saturday, November 19th. Finally, Cowen lifted their price objective on BeiGene from $200.00 to $213.00 in a research note on Thursday, November 10th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, BeiGene currently has a consensus rating of “Moderate Buy” and an average target price of $243.83.

BeiGene Company Profile

(Get Rating)

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

Featured Articles

Want to see what other hedge funds are holding BGNE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeiGene, Ltd. (NASDAQ:BGNEGet Rating).

Institutional Ownership by Quarter for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.